Press Release

Article

Akari Therapeutics Establishes US Headquarters in Boston

Author(s):

The expanded operations will also support the start of proline/alanine/serine (PAS)-nomacopan clinical trials in geographic atrophy (GA).

Akari Therapeutics, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announced on Aug. 18, 2023 its plan to establish its US headquarters in Boston, Mass. According to a company press release, the office will support expansion efforts in preparation for the beginning of enrollment in two registrational Phase III clinical trials for the recombinant protein therapeutic, nomacopan, in pediatric and adult hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The expanded operations will also support the start of proline/alanine/serine (PAS)-nomacopan clinical trials in geographic atrophy (GA).

Nomacopan has been tested in other clinical trials, including one for treating bullous pemphigold. The study findings suggested that a larger randomized clinical trial is needed to confirm the safety profile of the molecule to further be considered as a therapeutic option for bullous pemphigold (1).

“Boston is a vibrant epicenter of biotech innovation in the [United States] providing Akari access to … talent and other resources as we continue to build our US capabilities, advance our pivotal clinical trials, and work to realize the promise of nomacopan on behalf of patients and our investors,” said Rachelle Jacques, president and CEO, Akari, in the press release.

Enrollment for the Phase III clinical trials of nomacopan in pediatric and adult HSCT-TMA is expected to begin in late 2023 and 2024, respectively. The clinical trials of long-acting PAS-nomacopan as a potential treatment for GA is expected to start in 2024.

Reference

1. Sadik, C.D.; Rashid, H.; Hammers C. M.; et al. Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial. JAMA Dermatol. 2022, 158 (6), 641–649. DOI:10.1001/jamadermatol.2022.1156

Source: Akari Therapeutics

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content